Please note that slides are for review only and not to be repurposed or published.

DATA + PERSPECTIVES: CLINICAL INVESTIGATORS EXPLORE THE CURRENT AND FUTURE MANAGEMENT OF ER-POSITIVE BREAST CANCER

Introduction:
Dr Love

MODULE 1:
Use of Genomic Classifiers to Inform Therapeutic Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC) — Dr Sparano

MODULE 2:
Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive Metastatic BC (mBC) — Dr Goetz

MODULE 3:
Current and Future Management of ER-Positive mBC After Disease Progression on CDK4/6 Inhibition — Dr Burstein

MODULE 4:
Novel Applications of CDK4/6 Inhibitors; Ongoing Clinical Trials — Prof Johnston

Live Poll Results:
Download

DATA + PERSPECTIVES: CLINICAL INVESTIGATORS EXPLORE THE CURRENT AND FUTURE MANAGEMENT OF TRIPLE-NEGATIVE BREAST CANCER

Introduction:
Dr Love

MODULE 1:
Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making — Dr Hamilton

MODULE 2:
Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC — Dr Rugo

MODULE 3:
Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC — Dr Robson

MODULE 4:
Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials — Prof Loi

Live Poll Results:
Download

DATA + PERSPECTIVES: CLINICAL INVESTIGATORS EXPLORE THE CURRENT AND FUTURE MANAGEMENT OF HER2-POSITIVE BREAST CANCER

Introduction:
Dr Love

MODULE 1:
Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy — Dr Carey

MODULE 2:
Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC — Dr Piccart-Gebhart

MODULE 3:
Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC) — Dr Brufsky

MODULE 4:
Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC — Dr Hurvitz

Live Poll Results:
Download